Astria Therapeutics, Inc.

NasdaqGM:ATXS Lagerbericht

Marktkapitalisierung: US$718.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Astria Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Für Astria Therapeutics wird ein Gewinn- und Umsatzwachstum von 43% bzw. 57.5% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 2.1% pro Jahr sinken soll.

Wichtige Informationen

43.0%

Wachstumsrate der Gewinne

-2.15%

EPS-Wachstumsrate

Biotechs Gewinnwachstum25.2%
Wachstumsrate der Einnahmen57.5%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert26 Jan 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • Nov 30

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Summary I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks. While deal risks exist, they are considered minimal; with limited upside from current prices, I have exited my existing position. Read the full article on Seeking Alpha
Analyseartikel • Jul 08

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analyseartikel • Mar 13

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 18

Astria Therapeutics: A High-Conviction Bet On HAE

Summary Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation. Astria's strategic focus on patient-centric dosing regimens and regulatory strength could reshape treatment landscapes, but clinical and commercial execution remains crucial for success. Read the full article on Seeking Alpha
Seeking Alpha • Nov 27

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Summary Astria Therapeutics, Inc.'s STAR-0215 shows 90-96% reduction in HAE attack frequency, with a twice-a-year dosing regimen, positioning it as a transformative therapy. The company has a strong cash balance of $344 million, ensuring a runway until 2027, supporting continued development and trials. Competitive positioning is strong, with STAR-0215 outperforming existing treatments like Takhzyro and Haegarda in both efficacy and dosing convenience. Risks are minimal given the promising data, making ATXS stock a buy due to its excellent data, market potential, and upcoming catalysts. Read the full article on Seeking Alpha
Analyseartikel • Nov 14

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Astria Therapeutics...
Analyseartikel • Jul 11

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 24

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Summary Astria Therapeutics stock has fallen 40% since early 2023, but promising early data for its candidate STAR-0215 in treating HAE is helping drive analyst Buy ratings. ATXS stock has a compound called STAR-0310 in development for an immune disorder, with plans for a Phase 1a study in 2025. Despite positive early data for STAR-0215, competition in the HAE market is fierce and likely to get more crowded with promising new treatments on the horizon. An updated analysis of Astria Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 04

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Summary Astria Therapeutics (formerly Catabasis Pharmaceuticals) acquired Quellis Biosciences and its lead program, STAR-0215, for the treatment of hereditary angioedema (HAE) in 2021. The company has successfully completed a Phase 1 study for STAR-0215, demonstrating positive results in terms of safety, tolerability, and efficacy. Astria is now moving forward with a Phase 1b/2 study to establish proof-of-concept for STAR-0215 in HAE patients, with initial results expected in Q1 2024. The promise of HAE data in Q124 appears to have lifted the share price and allowed the company to raise funds. If the promise of upcoming is already baked into the share price, given how far behind the competition Astria is in HAE, and in atopic dermatitis with a second candidate, I would give its stock a "sell" rating. Read the full article on Seeking Alpha
Analyseartikel • Dec 10

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analyseartikel • Jul 27

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, Astria Therapeutics...
Analyseartikel • Apr 03

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analyseartikel • Nov 30

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Aug 01

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jul 15

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Astria Therapeutics (NASDAQ:ATXS) names more than 20 years of clinical development experience in rare diseases and other indications Chris Morabito, M.D., as Chief Medical Officer.  Dr. Morabito most recently served as the Chief Medical Officer at Fulcrum Therapeutics.
Seeking Alpha • Jun 30

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

After edasalonexent's failure last year, Catabasis Pharmaceuticals pivoted to the HAE market through the acquisition of Quellis Biosciences. The acquisition brought QLS-215, a preclinical stage monoclonal antibody with a potentially improved profile compared to prophylactic market leader Takhzyro. Much longer half-life and increased potency could result in less frequent administration and it could also improve efficacy. The HAE market is increasingly competitive with additional promising therapies in development, but if preclinical data of QLS-215 translate well into humans, Catabasis could deliver significant gains in the following years.

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:ATXS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202844N/A-99N/A1
12/31/2027N/AN/A-141N/A1
12/31/2026N/AN/A-129N/A2
12/31/202516-119-106N/A2
9/30/20251-124-120-120N/A
6/30/2025N/A-117-116-115N/A
3/31/2025N/A-108-96-96N/A
12/31/2024N/A-94-82-81N/A
9/30/2024N/A-100-94-94N/A
6/30/2024N/A-93-81-80N/A
3/31/2024N/A-82-74-74N/A
12/31/2023N/A-73-68-68N/A
9/30/2023N/A-55-49-49N/A
6/30/2023N/A-49-45-45N/A
3/31/2023N/A-48-44-44N/A
12/31/2022N/A-52-44-44N/A
9/30/2022N/A-48-39-39N/A
6/30/2022N/A-44-37-37N/A
3/31/2022N/A-65-34-34N/A
12/31/2021N/A-219-30-30N/A
9/30/2021N/A-219-32-32N/A
6/30/2021N/A-222-34-34N/A
3/31/2021N/A-199-34-34N/A
12/31/2020N/A-37-33-32N/A
9/30/2020N/A-35-32-32N/A
6/30/2020N/A-31-29-29N/A
3/31/2020N/A-28-27-27N/A
12/31/2019N/A-26-27-27N/A
9/30/2019N/A-26-24-24N/A
6/30/2019N/A-25N/A-23N/A
3/31/2019N/A-24N/A-23N/A
12/31/2018N/A-26N/A-23N/A
9/30/20180-25N/A-24N/A
6/30/20181-27N/A-25N/A
3/31/20181-27N/A-26N/A
12/31/20171-27N/A-27N/A
9/30/20170-31N/A-29N/A
6/30/2017N/A-32N/A-29N/A
3/31/2017N/A-35N/A-32N/A
12/31/2016N/A-36N/A-33N/A
9/30/2016N/A-37N/A-34N/A
6/30/2016N/A-37N/A-35N/A
3/31/2016N/A-36N/A-32N/A
12/31/2015N/A-33N/A-30N/A
9/30/2015N/A-29N/A-27N/A
6/30/2015N/A-27N/A-24N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ATXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ATXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ATXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ATXSDie Einnahmen des Unternehmens (57.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.7% pro Jahr).

Hohe Wachstumseinnahmen: ATXSDie Einnahmen des Unternehmens (57.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ATXS in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/01/27 10:22
Aktienkurs zum Tagesende2026/01/22 00:00
Gewinne2025/09/30
Jährliche Einnahmen2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Astria Therapeutics, Inc. wird von 1 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jonathan WollebenCitizens JMP Securities, LLC